ArticleOrphanet journal of rare diseases2021
French recommendations for the management of systemic sclerosis.
Article in Orphanet journal of rare diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 79 citations in OpenAlex.
- Pulmonary arterial hypertension with signs of venous/capillary involvement in connective tissue diseases: paradigms and paradoxes.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Combination therapy with mycophenolate mofetil, nintedanib, and tocilizumab in a patient with progressive systemic sclerosis-associated interstitial lung disease : A case report and a literature review.Zeitschrift fur Rheumatologie · 2026Review
- The impact of vertebral fractures on pulmonary function tests in patients with interstitial lung disease: a cross-sectional study.Respiratory research · 2026Article
- Arrhythmias in Systemic Sclerosis: A Call for Interdisciplinarity Teams.Life (Basel, Switzerland) · 2025Review
- Immunosuppressive Drugs in Early Systemic Sclerosis and Prevention of Damage Accrual.Arthritis care & research · 2025Observational
- Systemic sclerosis-related fecal incontinence: a scoping review focusing on a neglected manifestation.Rheumatology (Oxford, England) · 2025Article
- Cardiopulmonary Exercise Testing: Deciphering Cardiovascular Complications in Systemic Sclerosis.Reviews in cardiovascular medicine · 2025Review
- A Practical Multidisciplinary Approach to Identifying Interstitial Lung Disease in Systemic Autoimmune Rheumatic Diseases: A Clinician's Narrative Review.Diagnostics (Basel, Switzerland) · 2024Review
- Usefulness of monitoring mycophenolic acid exposure in systemic sclerosis-related interstitial lung disease: a retrospective cohort study.BMC pulmonary medicine · 2024Article
- Heart involvement in patients with systemic sclerosis-what have we learned about it in the last 5 years.Rheumatology international · 2024Review
- Article
- History of pre-eclampsia does not appear to be a risk factor for vascular phenotype in women with systemic sclerosis.RMD open · 2024Observational
- The frequency and clinical associations of opioid use in systemic sclerosis.Rheumatology advances in practice · 2024Article
- The validity and reliability of the Turkish version of the Brief Fear of Negative Evaluation Scale - straight forwardly in patients with systemic sclerosis.Malawi medical journal : the journal of Medical Association of Malawi · 2023Article
- Systemic sclerosis. Part II: perioperative considerations.BJA education · 2023Review
- Systemic sclerosis. Part I: epidemiology, diagnosis and therapy.BJA education · 2023Review
- Systemic sclerosis.Lancet (London, England) · 2023Review
- Screening tool development for hand surgery referrals in systemic sclerosis.Clinics (Sao Paulo, Brazil) · 2023Article
- HIV-Associated Systemic Sclerosis: Literature Review and a Rare Case Report.International journal of environmental research and public health · 2022Review
- New Era in Systemic Sclerosis Treatment: Recently Approved Therapeutics.Journal of clinical medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 17 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic sclerosis (SSc) is a generalized disease of the connective tissue, arterioles, and microvessels, characterized by the appearance of fibrosis and vascular obliteration. There are two main phenotypical forms of SSc: a diffuse cutaneous form that extends towards the proximal region of the limbs and/or torso, and a limited cutaneous form where the cutaneous sclerosis only affects the extremities of the limbs (without passing beyond the elbows and knees). There also exists in less than 10% of cases forms that never involve the skin. This is called SSc sine scleroderma. The prognosis depends essentially on the occurrence of visceral damage and more particularly interstitial lung disease (which is sometimes severe), pulmonary arterial hypertension, or primary cardiac damage, which represent the three commonest causes of mortality in SSc. Another type of involvement with poor prognosis, scleroderma renal crisis, is rare (less than 5% of cases). Cutaneous extension is also an important parameter, with the diffuse cutaneous forms having less favorable prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.